April 2015

New Product - Lemtrada

Lemtrada (alemtuzumab (rch)) is a recombinant DNA derived humanized monoclonal antibody directed against the 21‑28 kD cell surface glycoprotein, CD52. Alemtuzumab (rch) is produced in mammalian cell (Chinese hamster ovary) suspension culture in a nutrient medium. Alemtuzumab binds to CD52, a cell surface antigen present at high levels on T and B lymphocytes, and at lower levels on natural killer cells, monocytes, and macrophages. There is little or no CD52 detected on neutrophils, plasma cells, or bone marrow stem cells. Alemtuzumab acts through antibody dependent cellular cytolysis and complement mediated lysis following cell surface binding to T and B lymphocytes. The mechanism by which alemtuzumab exerts its therapeutic effects in MS is unknown, but may involve immunomodulation through the depletion and repopulation of lymphocytes. Lemtrada is indicated for the treatment of relapsing forms of multiple sclerosis (MS) for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses. Lemtrada is contraindicated in hypersensitivity or anaphylactic reactions to alemtuzumab, to murine proteins and in HIV infection. Lemtrada is available as a concentrate solution for infusion in a 2 mL glass vial filled to deliver 1.2 mL of 10 mg/mL solution (12 mg alemtuzumab).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629